Zydus Lifesciences gets USFDA approval for angina, high blood pressure drug
The company has received final approval from the US Food and Drug Administration (USFDA) for Diltiazem Hydrochloride tablets in strengths of 30 mg, 60 mg, 90 mg, and 120 mg, the drug maker said in a statement.
Diltiazem Hydrochloride Tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
It belongs to a class of drugs called calcium-channel blockers. Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle.
As per IQVIA MAT June 2025 data, Diltiazem Hydrochloride Tablets had annual sales of USD 13.9 million in the US. PTI MSS DRR
view comments
First Published:
August 11, 2025, 13:00 IST
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Sowa Rigpa healthcare facility in Arunachal soon: NISR director
Leh: The National Institute of Sowa Rigpa (NISR), an autonomous body working on this traditional Himalayan system of medicine, is set to open a healthcare facility in Arunachal Pradesh, a top official said. Within five years of its establishment, this institute under the ministry of Ayush has already enrolled its fifth batch of students in the undergraduate course, he said. "Sowa Rigpa is recognised by the government of India as a traditional medical system under the Ayush ministry . All the systems of medicine under the ministry have a central institute each, and in line with this, the NISR was announced by the prime minister in 2019. After necessary approvals, the institute started functioning in 2020," NISR director Padma Gurmet told PTI in an interview here. One of the oldest medical traditions in the world, the term 'Sowa-Rigpa' means 'knowledge of healing' in Bhoti language. This system is popular in Himalayan societies such as Ladakh, Himachal Pradesh (Spiti and Lahoul), Jammu and Kashmir, West Bengal (Darjeeling), Arunachal Pradesh, and Sikkim. It is also practiced in some parts of China, Mongolia, Nepal, Russia and Bhutan. Gurmet said the main objectives of the institute are to impart quality education in the Sowa Rigpa system of medicine , conduct research in a scientific line and also cater to public health in the Himalayan region. He maintained that NISR's progress has been fast as it launched its five-year undergraduate (UG) programme within the first year of establishment. The National Commission for Indian System of Medicine conducts the NEET for admission into the Bachelor of Sowa Rigpa Medicine and Surgery programme run at NISR. "We enrolled 10 students in the first year, who will be passing out next year. The fifth batch of students has been inducted this year based on performance in the national-level entrance exam," the director said. On expansion plans, Gurmet said NISR has been conducting outreach programmes such as seminars and conferences in different places, including Arunachal Pradesh and Sikkim. "We are now in the process of establishing a healthcare setup in Arunachal Pradesh. It will be done in two-three months. After that, we will try to open another campus in Sikkim," he said. The director said infrastructure development of the NISR is also progressing rapidly. "The central government has allocated Rs 40 crore for the first phase of construction. A new academic building is coming up, while hostels and a new hospital are in the pipeline. The construction should be completed in three to four years," he added. Gurmet also emphasised the need for adequate manpower to run the institute and its facilities. A total of 49 posts, including teaching, laboratory, and support staff, have been sanctioned, with the second phase of recruitment currently underway, he added. PTI
News18
5 hours ago
- News18
Apollo Hospitals posts 42 pc jump in profit to Rs 433 cr in Q1
New Delhi, Aug 12 (PTI) Apollo Hospitals Enterprise Ltd on Tuesday reported a 42 per cent jump in profit after tax to Rs 433 crore in the June quarter. The healthcare services provider had reported a PAT of Rs 305 crore in the year-ago period, according to a company release. Revenues rose 15 per cent to Rs 5,842 crore in the first quarter of the current fiscal year from Rs 5,086 crore in Q1 FY25, it said. Healthcare services revenue rose 11 per cent to Rs 2,935 crore in the first quarter of FY26 against Rs 2,637 crore in Q1 FY25, the statement said. Apollo Health and Lifestyle revenue rose 19 per cent to Rs 435 crore from Rs 366 crore in the year-ago period. view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
News18
6 hours ago
- News18
Cohance Lifesciences announces USD 10 mn investment in US-based arm
New Delhi, Aug 12 (PTI) Cohance Lifesciences on Tuesday announced a strategic investment of USD 10 million (around Rs 87.6 crore) to expand bioconjugation capabilities at its US-based subsidiary, NJ Bio. The investment advances Cohance's global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply, the company said in a statement. The common good manufacturing practices (cGMP) compliant bioconjugation suite at NJ Bio's Princeton, New Jersey, facility significantly strengthens the company's capabilities to deliver fully integrated Antibody-Drug Conjugate (ADC) solutions, it added. 'The investment … strengthening our footprint in the rapidly growing ADC space. By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster," Vivek Sharma, Executive Chairman, Cohance Lifesciences, said. In a separate statement, Cohance announced a Rs 23 crore investment and significant progress on its new oligonucleotide building block manufacturing facility in Hyderabad. 'Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply," the company said. Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global Contract Research, Development, and Manufacturing Organization (CRDMO), formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. PTI MSS MR view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
